| Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors M Ginj, H Zhang, B Waser, R Cescato, D Wild, X Wang, J Erchegyi, ... Proceedings of the National Academy of Sciences 103 (44), 16436-16441, 2006 | 575 | 2006 |
| DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals D Wild, JS Schmitt, M Ginj, HR Mäcke, BF Bernard, E Krenning, ... European journal of nuclear medicine and molecular imaging 30, 1338-1347, 2003 | 382 | 2003 |
| Glucagon-like peptide-1 receptor imaging for localization of insulinomas E Christ, D Wild, F Forrer, M Brandle, R Sahli, T Clerici, B Gloor, F Martius, ... The Journal of Clinical Endocrinology & Metabolism 94 (11), 4398-4405, 2009 | 349 | 2009 |
| Somatostatin receptor antagonists for imaging and therapy M Fani, GP Nicolas, D Wild Journal of nuclear medicine 58 (Supplement 2), 61S-66S, 2017 | 244 | 2017 |
| Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study D Wild, M Fani, R Fischer, L Del Pozzo, F Kaul, S Krebs, JEF Rivier, ... Journal of nuclear medicine 55 (8), 1248-1252, 2014 | 238 | 2014 |
| Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors D Wild, JB Bomanji, P Benkert, H Maecke, PJ Ell, JC Reubi, ME Caplin Journal of Nuclear Medicine 54 (3), 364-372, 2013 | 237 | 2013 |
| [Lys40 (Ahx-DTPA-111In) NH2] exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting D Wild, M Béhé, A Wicki, D Storch, B Waser, M Gotthardt, B Keil, ... Journal of Nuclear Medicine 47 (12), 2025-2033, 2006 | 234 | 2006 |
| Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas D Wild, E Christ, ME Caplin, TR Kurzawinski, F Forrer, M Brändle, ... Journal of Nuclear Medicine 52 (7), 1073-1078, 2011 | 231 | 2011 |
| Glucagon-like peptide 1–receptor scans to localize occult insulinomas D Wild, H Mäcke, E Christ, B Gloor, JC Reubi New England Journal of Medicine 359 (7), 766-768, 2008 | 231 | 2008 |
| 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 D Wild, HR Mäcke, B Waser, JC Reubi, M Ginj, H Rasch, J Müller-Brand, ... European journal of nuclear medicine and molecular imaging 32, 724-724, 2005 | 226 | 2005 |
| First clinical evidence that imaging with somatostatin receptor antagonists is feasible D Wild, M Fani, M Behe, I Brink, JEF Rivier, JC Reubi, HR Maecke, ... Journal of nuclear Medicine 52 (9), 1412-1417, 2011 | 208 | 2011 |
| Exendin-4–based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT D Wild, A Wicki, R Mansi, M Béhé, B Keil, P Bernhardt, G Christofori, ... Journal of Nuclear Medicine 51 (7), 1059-1067, 2010 | 191 | 2010 |
| Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study E Christ, D Wild, S Ederer, M Béhé, G Nicolas, ME Caplin, M Brändle, ... The lancet Diabetes & endocrinology 1 (2), 115-122, 2013 | 184 | 2013 |
| DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours H Zhang, J Schuhmacher, B Waser, D Wild, M Eisenhut, JC Reubi, ... European journal of nuclear medicine and molecular imaging 34, 1198-1208, 2007 | 168 | 2007 |
| Consensus on molecular imaging and theranostics in neuroendocrine neoplasms V Ambrosini, J Kunikowska, E Baudin, L Bodei, C Bouvier, J Capdevila, ... European journal of cancer 146, 56-73, 2021 | 162 | 2021 |
| Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN) D Wild, M Frischknecht, H Zhang, A Morgenstern, F Bruchertseifer, ... Cancer research 71 (3), 1009-1018, 2011 | 153 | 2011 |
| Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study GP Nicolas, N Schreiter, F Kaul, J Uiters, H Bouterfa, J Kaufmann, ... Journal of Nuclear Medicine 59 (6), 915-921, 2018 | 143 | 2018 |
| Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor … N Spaeth, MT Wyss, B Weber, S Scheidegger, A Lutz, J Verwey, ... Journal of Nuclear Medicine 45 (11), 1931-1938, 2004 | 138 | 2004 |
| GLP-1–receptor scanning for imaging of human beta cells transplanted in muscle F Pattou, J Kerr-Conte, D Wild New England Journal of Medicine 363 (13), 1289-1290, 2010 | 136 | 2010 |
| Biodistribution, pharmacokinetics, and dosimetry of 177Lu-, 90Y-, and 111In-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist 177Lu-DOTATATE: the … GP Nicolas, R Mansi, L McDougall, J Kaufmann, H Bouterfa, D Wild, ... Journal of Nuclear Medicine 58 (9), 1435-1441, 2017 | 130 | 2017 |
Jean Claude ReubiProfessor of Pathology, Cell Biology, University of Bern在 pathology.unibe.ch 的电子邮件经过验证
